{
    "nct_id": "NCT04198623",
    "official_title": "A Phase II Study, Evaluating the Efficacy of Montelukast in Reducing the Incidence and Severity of Monoclonal Antibodies Associated Infusion Reactions",
    "inclusion_criteria": "1. Patients must be at least 18 years.\n2. Able to provide consent for study participation (English and Spanish).\n3. Patients with hematologic disorders or malignancies starting on any of the following monoclonal antibodies alone or in combination with chemotherapy (Blinatumomab, Daratumumab, Elotuzumab, Gemtuzumab, Obinutuzumab, and Rituximab).\n4. Able to tolerate leukotriene antagonist including Montelukast.\n5. Able to tolerate oral intake.\n6. Available for follow up by phone and on site.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients undergoing treatment with above monoclonal antibodies for indications other than stated in above eligibility criteria.\n2. Patients who cannot provide informed consent in English or Spanish.\n3. Patients taking Montelukast or other leukotriene antagonists for other indications at the time of screening.\n4. Known allergic reactions to Montelukast or other leukotriene inhibitors.\n5. On monoclonal antibodies other than the ones being studied (Blinatumomab, Daratumumab, Elotuzumab, Gemtuzumab, Obinutuzumab, and Rituximab).\n6. History of uncontrolled depression or suicidal ideation or psychiatric illness.\n7. Known Severe Hepatic Impairment (AST>10x ULN; ALT>10x ULN; ALP>10x ULN; and/or Bilirubin >5x ULN).\n8. Patient with eosinophilic vasculitis.\n9. Unable to comply with phone or in person follow-up.\n10. Patients participating in another clinical trial.\n11. Pregnancy",
    "miscellaneous_criteria": ""
}